Abstract
Aim:
The objectives of this study were to investigate the inhibitory action of telmisartan, a selective angiotensin II type 1 receptor antagonist, on hKv1.5 and human ether-a-go-go-related gene (HERG) channels expressed on Xenopus laevis oocytes.
Methods:
hKv1.5 and HERG channels were expressed on Xenopus laevis oocytes and studied using the 2-microelectrode voltage clamp technique.
Results:
In hKv1.5 channels, telmisartan produced a voltage- and concentration-dependent inhibition; the efficacies of blockade were different at peak and 1.5 s end-pulse currents, which were 7.75%±2.39% (half-maximal inhibition concentration [IC50]=2.25±0.97 μmol/L) and 52.64%±3.77% (IC50=0.82±0.39 μmol/L) at 1 μmol/L telmisartan, respectively. Meanwhile, telmisartan accelerated the inactivation of the channels. However, telmisartan exhibited a low affinity for HERG channels (IC50=24.35±5.06 μmol/L); the blockade was voltage- and concentration-dependent. Telmisartan preferentially blocked open-state HERG channels. The slow time constants of deactivation were accelerated (n=6, P<0.05), which was inconsistent with the “foot-in-the-door” effect.
Conclusion:
Telmisartan blocks hKv1.5 potassium channels involving open and inactivated states at plasma concentration levels of therapeutic doses; whereas the blockade of HERG channels occurs only at supra plasma concentration levels of therapeutic doses and preferentially in open and closed-state channels.
Article PDF
Similar content being viewed by others
References
Burnier M, Brunner HR . Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.
Stangier J, Su C, Roth W . Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149–67.
Delpón E, Caballero R, Gómez R, Núñez L, Tamargo J . Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends Pharmacol Sci 2005; 26: 155–61.
Tristani-Firouzi M, Sanguinetti MC . Structural determinants and biophysical properties of HERG and KCNQ1 channel gating. J Mol Cell Cardiol 2003; 35: 27–35.
Roden DM, George AL Jr . Structure and function of cardiac sodium and potassium channels. Am J Physiol 1997; 273: H511–25.
Tamkun MM, Knoth KM, Walbridge JA, Kroemer H, Roden DM, Glover DM . Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J 1991; 5: 331–7.
Wang Z, Fermini B, Nattel S . Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 1993; 73: 1061–76.
Sanguinetti MC, Jiang C, Curran ME, Keating MT . A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the I Kr potassium channel. Cell 1995; 81: 299–307.
Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, et al. MiRP1 forms I Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 175–87.
Caballero R, Delpón E, Valenzuela C, Longobardo M, Tamargo J . Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents. Circulation 2000; 101: 1199–205.
Wang X, Liao Y, Zou A, Li L, Tu D . Blockade action of ketanserin and increasing effect of potassium ion on Kv1.3 channels expressed in Xenopus oocytes. Pharmacol Res 2007; 56: 148–54.
Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ . Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003; 139: 887–98.
Trudeau MC, Warmke JW, Ganetzky B, Robertson GA . HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995; 269: 92–5.
Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC . Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem 2002; 277: 23 587–95.
Milnes JT, Dempsey CE, Ridley JM, Crociani O, Arcangeli A, Hancox JC, et al. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett 2003; 547 ( 1-3): 20–6.
Zhang H, Zhu B, Yao JA, Tseng GN . Differential effects of S6 mutations on binding of quinidine and 4-aminopyridine to rat isoform of Kv1.4: common site but different factors in determining blockers' binding affinity. J Pharmacol Exp Ther 1998; 287: 332–43.
Moreno I, Caballero R, González T, Arias C, Valenzuela C, Iriepa I, et al. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther 2003; 304: 862–73.
Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC . A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000; 97: 12329–33.
Su Z, Chen J, Martin RL, McDermott JS, Cox BF, Gopalakrishnan M, et al. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem Pharmacol 2006; 71: 278–86.
Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC . Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 2003; 63: 1051–8.
Keating MT, Sanguinetti MC . Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001; 104: 569–80.
Iskin S . Long QT syndromes and torsade de pointes. Lancet 1999; 354: 1625–33.
Cavero I, Mestre M, Guillon JM, Crumb W . Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000; 1: 947–73.
De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N . Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002; 25: 263–86.
Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32–45.
Caballero R, Delpón E, Valenzuela C, Longobardo M, Tamargo J . Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents. Circulation 2000; 101: 1199–205.
Fedida D, Wible B, Wang Z, Fermini B, Faust F, Nattel S, et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res 1993; 73: 210–6.
Snyders DJ, Tamkun MM, Bennett PB . A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 1993; 101: 513–43.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Natural Science Foundation of China (No 30470711).
Rights and permissions
About this article
Cite this article
Tu, Dn., Liao, Yh., Zou, Ar. et al. Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes. Acta Pharmacol Sin 29, 913–922 (2008). https://doi.org/10.1111/j.1745-7254.2008.00839.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00839.x
- Springer Nature Singapore Pte Ltd.
Keywords
This article is cited by
-
Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention
Current Hypertension Reports (2015)
-
18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels
Acta Pharmacologica Sinica (2012)
-
The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action
Pflügers Archiv - European Journal of Physiology (2012)
-
Effect of matrine on human ether à go-go related gene (HERG) channels expressed in Chinese hamster ovary cells
Chinese Journal of Integrative Medicine (2010)